• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性肥厚型心肌病患者二尖瓣反流的预后价值。

Prognostic Value of Mitral Regurgitation in Patients with Primary Hypertrophic Cardiomyopathy.

机构信息

Clinic for Cardiology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.

Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

出版信息

Medicina (Kaunas). 2023 Oct 9;59(10):1798. doi: 10.3390/medicina59101798.

DOI:10.3390/medicina59101798
PMID:37893516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10608691/
Abstract

: Mitral valve pathology and mitral regurgitation (MR) are very common in patients with hypertrophic cardiomyopathy (HCM), and the evaluation of mitral valve anatomy and degree of MR is important in patients with HCM. The aim of our study was to examine the potential influence of moderate or moderately severe MR on the prognosis, clinical presentation, and structural characteristics of HCM patients. : A prospective study examined 176 patients diagnosed with primary asymmetric HCM. According to the severity of the MR, the patients were divided into two groups: Group 1 ( = 116) with no/trace or mild MR and Group 2 ( = 60) with moderate or moderately severe MR. All patients had clinical and echocardiographic examinations, as well as a 24 h Holter ECG. : Group 2 had significantly more often the presence of the obstructive type of HCM ( < 0.001), syncope ( = 0.030), NYHA II class ( < 0.001), and atrial fibrillation ( = 0.023). Also, Group 2 had an enlarged left atrial dimension ( < 0.001), left atrial volume index ( < 0.001), and indirectly measured systolic pressure in the right ventricle ( < 0.001). Patients with a higher grade of MR had a significantly higher E/e' ( < 0.001) and, as a result, higher values of Nt pro BNP values ( < 0.001) compared to Group 1. Kaplan-Meier analysis demonstrated that the event-free survival rate during a median follow-up of 88 (IQR 40-112) months was significantly higher in Group 1 compared to Group 2 (84% vs. 45% at 8 years; log-rank 20.4, < 0.001). After adjustment for relevant confounders, the presence of moderate or moderately severe MR remained as an independent predictor of adverse outcomes (HR 2.788; 95% CI 1.221-6.364, = 0.015). : The presence of moderate or moderately severe MR was associated with unfavorable long-term outcomes in HCM patients.

摘要

二尖瓣病变和二尖瓣反流(MR)在肥厚型心肌病(HCM)患者中非常常见,评估 HCM 患者的二尖瓣解剖结构和 MR 程度非常重要。我们的研究旨在探讨中度或重度 MR 对 HCM 患者预后、临床表现和结构特征的潜在影响。

一项前瞻性研究检查了 176 名被诊断为原发性非对称性 HCM 的患者。根据 MR 的严重程度,患者分为两组:无/微量或轻度 MR 的第 1 组(n=116)和中度或重度 MR 的第 2 组(n=60)。所有患者均进行了临床和超声心动图检查,以及 24 小时动态心电图检查。

第 2 组更常出现梗阻型 HCM(<0.001)、晕厥(=0.030)、NYHA II 级(<0.001)和心房颤动(=0.023)。此外,第 2 组的左心房内径(<0.001)、左心房容积指数(<0.001)和间接测量的右心室收缩压(<0.001)更大。MR 程度较高的患者 E/e'显著更高(<0.001),因此 Nt pro BNP 值更高(<0.001)。与第 1 组相比,第 2 组的事件无进展生存率在中位 88(IQR 40-112)个月的随访中明显较低(8 年时为 84% vs. 45%;对数秩检验 20.4,<0.001)。在校正相关混杂因素后,中度或重度 MR 的存在仍然是不良结局的独立预测因素(HR 2.788;95%CI 1.221-6.364,=0.015)。

中度或重度 MR 的存在与 HCM 患者的不良长期预后相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b593/10608691/632c1be4ced3/medicina-59-01798-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b593/10608691/03d7e4cd1694/medicina-59-01798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b593/10608691/632c1be4ced3/medicina-59-01798-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b593/10608691/03d7e4cd1694/medicina-59-01798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b593/10608691/632c1be4ced3/medicina-59-01798-g002.jpg

相似文献

1
Prognostic Value of Mitral Regurgitation in Patients with Primary Hypertrophic Cardiomyopathy.原发性肥厚型心肌病患者二尖瓣反流的预后价值。
Medicina (Kaunas). 2023 Oct 9;59(10):1798. doi: 10.3390/medicina59101798.
2
Evaluation and implications of mitral regurgitation using cMRI in patients with hypertrophic cardiomyopathy.应用心脏磁共振成像评估肥厚型心肌病患者的二尖瓣反流及其意义。
Eur Rev Med Pharmacol Sci. 2023 May;27(9):4006-4018. doi: 10.26355/eurrev_202305_32306.
3
Prognostic Implication of Mitral Valve Disease and Its Progression in East Asian Patients With Hypertrophic Cardiomyopathy.肥厚型心肌病东亚患者二尖瓣病变及其进展的预后意义。
J Am Heart Assoc. 2023 Feb 7;12(3):e024792. doi: 10.1161/JAHA.121.024792. Epub 2023 Jan 23.
4
Impact of exercise-induced mitral regurgitation on hypertrophic cardiomyopathy outcomes.运动诱发的二尖瓣反流对肥厚型心肌病结局的影响。
Eur Heart J Cardiovasc Imaging. 2016 Oct;17(10):1110-7. doi: 10.1093/ehjci/jev242. Epub 2015 Oct 16.
5
Prognostic Significance of Non-Dilated Left Ventricular Size and Mitral Regurgitation in Patients With Dilated Phase of Hypertrophic Cardiomyopathy.肥厚型心肌病扩张期患者非扩张性左心室大小及二尖瓣反流的预后意义
Int Heart J. 2017 Feb 7;58(1):63-68. doi: 10.1536/ihj.16-109. Epub 2017 Jan 11.
6
N-terminal pro-brain natriuretic peptide is related with coronary flow velocity reserve and diastolic dysfunction in patients with asymmetric hypertrophic cardiomyopathy.N末端前脑钠肽与非对称性肥厚型心肌病患者的冠状动脉血流储备及舒张功能障碍相关。
J Cardiol. 2017 Oct;70(4):323-328. doi: 10.1016/j.jjcc.2017.02.008. Epub 2017 Mar 21.
7
Echocardiographic and clinical outcomes of patients undergoing septal myectomy plus anterior mitral leaflet extension for hypertrophic cardiomyopathy.肥厚型心肌病行心肌切除术联合二尖瓣前叶延长术患者的超声心动图和临床转归。
Rev Cardiovasc Med. 2021 Sep 24;22(3):983-990. doi: 10.31083/j.rcm2203107.
8
4D flow MRI left atrial kinetic energy in hypertrophic cardiomyopathy is associated with mitral regurgitation and left ventricular outflow tract obstruction.4D 流 MRI 肥厚型心肌病左房动能与二尖瓣反流和左心室流出道梗阻相关。
Int J Cardiovasc Imaging. 2021 Sep;37(9):2755-2765. doi: 10.1007/s10554-021-02167-6. Epub 2021 Feb 1.
9
Importance of surgical expertise in septal myectomy for obstructive hypertrophic cardiomyopathy.手术专长在梗阻性肥厚型心肌病室间隔心肌切除术的重要性。
Gen Thorac Cardiovasc Surg. 2020 Oct;68(10):1094-1100. doi: 10.1007/s11748-020-01320-7. Epub 2020 Feb 27.
10
Comparison of mitral regurgitation severity assessments based on magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy.基于磁共振成像和超声心动图对肥厚型心肌病患者二尖瓣反流严重程度的评估比较。
Sci Rep. 2021 Oct 6;11(1):19902. doi: 10.1038/s41598-021-99446-y.

引用本文的文献

1
Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy.肥厚型心肌病中的心房颤动与血栓栓塞风险
J Cardiovasc Imaging. 2025 Aug 25;33(1):12. doi: 10.1186/s44348-025-00057-2.
2
Mitral regurgitation in patients with hypertrophic cardiomyopathy: a case series.肥厚型心肌病患者的二尖瓣反流:病例系列
Eur Heart J Case Rep. 2025 Mar 3;9(3):ytaf113. doi: 10.1093/ehjcr/ytaf113. eCollection 2025 Mar.

本文引用的文献

1
Prognostic Implication of Mitral Valve Disease and Its Progression in East Asian Patients With Hypertrophic Cardiomyopathy.肥厚型心肌病东亚患者二尖瓣病变及其进展的预后意义。
J Am Heart Assoc. 2023 Feb 7;12(3):e024792. doi: 10.1161/JAHA.121.024792. Epub 2023 Jan 23.
2
Different mechanisms of mitral regurgitation in hypertrophic cardiomyopathy: A clinical case and literature review.肥厚型心肌病中二尖瓣反流的不同机制:一例临床病例及文献综述
Front Cardiovasc Med. 2022 Oct 28;9:1020054. doi: 10.3389/fcvm.2022.1020054. eCollection 2022.
3
Pulmonary congestion during Exercise stress Echocardiography in Hypertrophic Cardiomyopathy.
肥厚型心肌病运动超声心动图检查时的肺充血。
Int J Cardiovasc Imaging. 2022 Dec;38(12):2593-2604. doi: 10.1007/s10554-022-02620-0. Epub 2022 Nov 2.
4
Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathy-An Analysis from the SILICOFCM Database.性别相关差异在肥厚型心肌病临床表型中的作用:来自 SILICOFCM 数据库的分析。
Medicina (Kaunas). 2022 Feb 18;58(2):314. doi: 10.3390/medicina58020314.
5
Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy.经胸多普勒超声心动图冠状动脉血流储备在不对称性肥厚型心肌病患者中的预测价值。
J Am Heart Assoc. 2021 Oct 19;10(20):e021936. doi: 10.1161/JAHA.120.021936. Epub 2021 Oct 12.
6
Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy.肥厚型心肌病患者运动时心率储备降低的预后价值
J Clin Med. 2021 Mar 24;10(7):1347. doi: 10.3390/jcm10071347.
7
Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy.肥厚型心肌病临床表型的遗传决定因素。
BMC Cardiovasc Disord. 2020 Dec 9;20(1):516. doi: 10.1186/s12872-020-01807-4.
8
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020 年 AHA/ACC 肥厚型心肌病患者诊断与治疗指南:概要:美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2020 Dec 22;76(25):3022-3055. doi: 10.1016/j.jacc.2020.08.044. Epub 2020 Nov 20.
9
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病(EXPLORER-HCM)的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
10
Exploring the Continuum of Hypertrophic Cardiomyopathy-From DNA to Clinical Expression.探索肥厚型心肌病的连续统:从 DNA 到临床表型。
Medicina (Kaunas). 2019 Jun 23;55(6):299. doi: 10.3390/medicina55060299.